Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APH-0201
- Development stage
- Preclinical
- Lead developer
- Aphios
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
APH-0201 is an orally bioavailable nanoformulation of betulinic acid, a pentacyclic triterpene small molecule naturally occurring in the bark of white birch trees. Developed by Aphios Corporation, APH-0201 is designed to treat melanoma by inducing the apoptosis pathway in cancer cells. While betulinic acid has demonstrated melanoma-specific cytotoxicity, its clinical application has historically been hindered by poor aqueous solubility and low bioavailability. APH-0201 utilizes Aphios' proprietary nanotechnology platforms to enhance the delivery and pharmacokinetic profile of the active ingredient. The drug is currently in preclinical development for the treatment of melanoma.
- Other names
- betulinic acid
Beyond the preview
Go deeper on APH-0201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APH-0201.